mgd009
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2015 (NCT02628535)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Colonic Neoplasms · Phase 1
- Melanoma · Phase 1
- Mesothelioma · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1
- Sarcoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Thyroid Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
CD3E activator
- CD276 antigenINHIBITOR
CD276 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- mgd009
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03406949 | Phase 1 | Feb 27, 2018 | MacroGenics |
| NCT02628535 | Phase 1 | Sep 1, 2015 | MacroGenics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MacroGenics | For profit | 2 | 2 | 1 | 2015 |
1 organizations
Page 1 / 1